Stoke Therapeutics is progressing its RNA-based treatment for Dravet Syndrome, with the Phase 3 EMPEROR trial for zorevunersen now fully enrolled. Top-line results are expected in the second half of 2027, with interim data at week 28 due in late December. The company has $343.5 million in cash, strong partnerships with Biogen and Acadia, and a manageable burn rate, providing financial stability through key milestones. Goldman Sachs values the stock at $44 per share, projecting peak sales of $1.5 billion and a 75% success probability, highlighting significant upside potential for investors.
Ethereum remains the dominant smart-contract platform with strong institutional support and a mature ecosystem, focusing on layer-2 scaling solutions. Solana offers faster, cheaper transactions with fees around $0.00025, attracting high-frequency app...
Uniswap's community will vote from July 19 to 26 on two proposals to activate protocol fee collection on v4 pools across seven blockchains and enable fees on v2 and v3 pools on Robinhood Chain. Fees collected will be used to burn UNI tokens, reducing...
Constellation Energy (CEG) controls over half of the US merchant nuclear pool, giving it the largest deliverable carbon-free inventory. Its investment appeal is based on structural scarcity, as the uncontracted nuclear supply is smaller than the grow...
On July 18, hackers briefly disabled the official website of Kenyan President William Ruto, defacing the homepage and demanding a ransom of five bitcoins to prevent a data leak. The government quickly responded by activating cybersecurity protocols a...
Investor Leo Nelissen continues to hold GE Aerospace shares despite its high earnings multiple of 40x, citing the company's dominant market position and resilient business model. He prioritizes long-term winners with strong competitive advantages and...
